NASDAQ:ONVO Organovo (ONVO) Stock Price, News & Analysis → The only AI company to buy (From Porter & Company) (Ad) Free ONVO Stock Alerts $1.00 -0.05 (-4.78%) (As of 06/4/2024 ET) Add Compare Share Share Today's Range$0.98▼$1.0150-Day Range$0.91▼$1.3552-Week Range$0.85▼$2.05Volume55,846 shsAverage Volume161,562 shsMarket Capitalization$9.99 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainSEC FilingsShort InterestTrends Get Organovo alerts: Email Address Ad Brooks EnterprisesHow’d you do in 20222022 was a rough year. At their worst, the S&P 500 was down over 25% and the NASDAQ was down over 35%, and to make things even more interesting the Fed was seemingly raising interest rates every week!Get those kind of results during the Great Financial Crisis, without having to study more About Organovo Stock (NASDAQ:ONVO)Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive 3D bioprinted human liver tissue with distinct hepatocellular and non-parenchymal cell compartments. The company was incorporated in 2007 and is headquartered in San Diego, California.Read More ONVO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ONVO Stock News HeadlinesJune 1, 2024 | americanbankingnews.comOrganovo Holdings, Inc. (NASDAQ:ONVO) Short Interest Down 16.7% in MayMay 28, 2024 | americanbankingnews.comOrganovo (NASDAQ:ONVO) Earns Sell Rating from Analysts at StockNews.comMay 21, 2024 | globenewswire.comOrganovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel DiseaseMay 14, 2024 | globenewswire.comOrganovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024)May 8, 2024 | globenewswire.comOrganovo Holdings, Inc. Announces Pricing of $5.25 Million Public OfferingMay 1, 2024 | finance.yahoo.comONVO Announces Very Positive Phase 2 ResultsApril 15, 2024 | msn.comWhy Organovo Stock Is Up TodayApril 15, 2024 | reuters.comOrganovo's fatty liver disease drug meets main goal in mid-stage studyApril 15, 2024 | globenewswire.comOrganovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to PlaceboFebruary 24, 2024 | benzinga.comOrganovo Holdings Stock (NASDAQ:ONVO) Earnings Dates and Earning CallsFebruary 10, 2024 | finance.yahoo.comOrganovo Holdings Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagFebruary 9, 2024 | morningstar.comOrganovo Holdings Inc ONVOFebruary 9, 2024 | finance.yahoo.comONVO Continues ProgressFebruary 8, 2024 | sfgate.comOrganovo: Fiscal Q3 Earnings SnapshotFebruary 8, 2024 | msn.comOrganovo Holdings Unveils Corporate Presentation OnlineJanuary 25, 2024 | finance.yahoo.comOrganovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis CongressJanuary 9, 2024 | finance.yahoo.comOrganovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn’s and Colitis CongressDecember 7, 2023 | finanznachrichten.deOrganovo, Inc.: Organovo Provides Timing for Release of FXR314 Phase 2 NASH ResultsDecember 6, 2023 | finance.yahoo.comOrganovo Provides Timing for Release of FXR314 Phase 2 NASH ResultsNovember 13, 2023 | msn.comOVNO Continues Developing Breakthrough TreatmentsNovember 13, 2023 | finance.yahoo.comCORRECTION – Organovo Highlights FXR314 Combination Therapy Potential and PlanNovember 11, 2023 | finance.yahoo.comOrganovo Holdings Second Quarter 2024 Earnings: US$0.46 loss per share (vs US$0.38 loss in 2Q 2023)November 8, 2023 | finance.yahoo.comOrganovo Highlights FXR314 Combination Therapy Potential and PlanNovember 7, 2023 | msn.comONVO, FATH and BYU among mid-day moversOctober 10, 2023 | finance.yahoo.comONVO: A Company With Great Technology to Impact Health CareSee More Headlines Receive ONVO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Organovo and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2019Today6/04/2024Next Earnings (Estimated)7/11/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:ONVO CUSIPN/A CIK1497253 Webwww.organovo.com Phone(858) 224-1000FaxN/AEmployees18Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-17,260,000.00 Net MarginsN/A Pretax Margin-7,885.54% Return on Equity-182.88% Return on Assets-138.52% Debt Debt-to-Equity RatioN/A Current Ratio3.67 Quick Ratio3.67 Sales & Book Value Annual Sales$370,000.00 Price / Sales27.00 Cash FlowN/A Price / Cash FlowN/A Book Value$1.76 per share Price / Book0.57Miscellaneous Outstanding Shares10,040,000Free Float9,538,000Market Cap$9.99 million OptionableOptionable Beta0.68 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Keith E. Murphy (Age 52)Executive Chairman Comp: $762.74kMr. Thomas P. Hess CPA (Age 60)MBA, President & CFO Comp: $199.32kMs. Vaidehi Joshi (Age 37)Director of Discovery Biology & Director Comp: $91.8kDr. Curtis M. Tyree Ph.D.Senior Vice President of Strategy & Business DevelopmentKey CompetitorsMicrobot MedicalNASDAQ:MBOTAchilles TherapeuticsNASDAQ:ACHLCyclo TherapeuticsNASDAQ:CYTHQuince TherapeuticsNASDAQ:QNCXNKGen BiotechNYSE:NKGNView All CompetitorsInsidersDavid GobelSold 19,607 sharesTotal: $31,763.34 ($1.62/share)View All Insider Transactions ONVO Stock Analysis - Frequently Asked Questions How have ONVO shares performed in 2024? Organovo's stock was trading at $1.11 at the beginning of the year. Since then, ONVO shares have decreased by 10.4% and is now trading at $0.9950. View the best growth stocks for 2024 here. Are investors shorting Organovo? Organovo saw a drop in short interest during the month of May. As of May 15th, there was short interest totaling 342,300 shares, a drop of 16.7% from the April 30th total of 410,700 shares. Based on an average trading volume of 1,010,000 shares, the short-interest ratio is currently 0.3 days. View Organovo's Short Interest. When is Organovo's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, July 11th 2024. View our ONVO earnings forecast. How were Organovo's earnings last quarter? Organovo Holdings, Inc. (NASDAQ:ONVO) announced its earnings results on Thursday, August, 8th. The medical research company reported ($1.00) EPS for the quarter, hitting the consensus estimate of ($1.00). The medical research company had revenue of $0.67 million for the quarter, compared to the consensus estimate of $0.77 million. When did Organovo's stock split? Shares of Organovo reverse split on Wednesday, August 19th 2020. The 1-20 reverse split was announced on Monday, August 17th 2020. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, August 18th 2020. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What is Taylor Crouch's approval rating as Organovo's CEO? 3 employees have rated Organovo Chief Executive Officer Taylor Crouch on Glassdoor.com. Taylor Crouch has an approval rating of 38% among the company's employees. This puts Taylor Crouch in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Organovo own? Based on aggregate information from My MarketBeat watchlists, some companies that other Organovo investors own include Brainstorm Cell Therapeutics (BCLI), NVIDIA (NVDA), Aerojet Rocketdyne (AJRD), Blackstone (BX), LADENBURG THALM/SH SH (LTS), Advanced Micro Devices (AMD), Exelixis (EXEL), Micron Technology (MU), Novavax (NVAX) and OPKO Health (OPK). How do I buy shares of Organovo? Shares of ONVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ONVO) was last updated on 6/5/2024 by MarketBeat.com Staff From Our PartnersUrgent alert: open this for a huge profit potentialThis groundbreaking technology that Tim calls “Inception” isn’t being talked about anywhere… not on Fox, Yahoo...Timothy Sykes| SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises| SponsoredCollapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals| SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club| Sponsored[Webinar] Understanding Covered CallsDiscover the details of this option-selling strategy.OIC| SponsoredWhat’s Pelosi Buying Now?They Make the Top Investors Look Like Amateurs They beat the market for three years straight… avoided some ...Altimetry| SponsoredElon Musk’s Final Masterpiece: “X-9840”The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Ju...Paradigm Press| SponsoredWho are Nvidia’s Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings| Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Organovo Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Organovo With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.